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Background: One of the most important areas of Raman medical diagnostics is identification and characterization
of cancerous and noncancerous tissues. The methods based on Raman scattering has shown significant potential
for probing human breast tissue to provide valuable information for early diagnosis of breast cancer. A vibrational
fingerprint from the biological tissue provides information which can be used to identify, characterize and
discriminate structures in breast tissue, both in the normal and cancerous environment.
Results: The paper reviews recent progress in understanding structure and interactions at biological interfaces of
the human tissue by using confocal Raman imaging and IR spectroscopy. The important differences between the
noncancerous and cancerous human breast tissues were found in regions characteristic for vibrations of
carotenoids, fatty acids, proteins, and interfacial water. Particular attention was paid to the role played by
unsaturated fatty acids and their derivatives as well as carotenoids and interfacial water.
Conclusions: We demonstrate that Raman imaging has reached a clinically relevant level in regard to breast cancer
diagnosis applications. The results presented in the paper may have serious implications on understanding
mechanisms of interactions in living cells under realistically crowded conditions of biological tissue.
Keywords: Breast cancer biochemical imaging, Interfacial water, Raman imaging, IR spectroscopyBackground
The most important factors in improving the survival rate
for cancer patients are: reliable diagnosis for early detec-
tion, early treatment, and treatment response monitoring
providing with unequivocal data. There is a profound clin-
ical need for diagnostic tools to achieve these goals.
The current diagnosis or prevention methods are based
on X-Ray mammography, magnetic resonance imaging
(MRI), positron emission tomography (PET) and ultrason-
ography. X-Ray mammography is the golden standard of
imaging examination used for breast cancer diagnosis.
However, there are well-known limitations in terms of sen-
sitivity and specificity, especially when scanning patients
with high breast density, common in younger women. This
leads to relatively unsatisfying levels of false positive and
false negative results, as high as 75% and 34%, respectively
[1-3]. Moreover, mammography is not a specific screening
method, as it does not allow to differentiate between* Correspondence: abramczy@mitr.p.lodz.pl
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reproduction in any medium, provided the orbenign and malignant tumors. The second standard
method – ultrasonography is a fast and low-cost technique,
but has a low spatial resolution [4]. The MRI technique of-
fers a good contrast between different soft tissues of the
body, but has many drawbacks, like the long duration of
the examination and the cost of the instrument. It also
causes side effects in the patients like hyperthermia or a
negative impact on the patient’s kidneys, related to the use
of gadolinium contrast agent [5]. Positron Emission Tom-
ography (PET) is an appealing complementary technique
for breast imaging, but the image resolution of PET is low
and typically ranges between 4 and 7 mm. To improve
resolution and contrast between normal and cancerous
breast tissue a dedicated breast PET – Positron Emission
Mammography (PEM) has been developed [6-8].
To overcome major drawbacks of the standard tech-
niques, the optical methods such as diffuse optical tomog-
raphy–fluorescence mediated tomography [9,10], photo-
acoustic imaging [11], acousto-optical imaging [12] have
been developed to obtain a more accurate, rapid, inexpen-
sive, and non-destructive method of imaging. The optical
imaging systems are ideally suited for early detection of
intraepithelial diseases, including most cancers, and allowal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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methods offer several significant advantages over the
routine clinical imaging methods, including: a) non-
invasiveness through the use of safe, non-ionizing radiation,
b) display of contrast between soft tissues based on optical
properties of the tissue, c) facility for continuous bedside
monitoring, d) high spatial resolution (less than 1 micron
lateral resolution in visible range). Almost all of the widely
used methods of molecular diagnostics centered on protein
separation, amplification, and gene expression in target pro-
teins and nucleic acids involve fluorescence spectroscopy.
The confocal, laser-based fluorescence microscopy became
a golden standard for optical imaging and molecular diag-
nostics [13]. The disadvantage of fluorescence is that the
multiplexing capability of this technique is limited due to
the broad emission profile of fluorophores. This results in
difficulty in deconvoluting mixtures of signals.
Raman spectroscopy has many advantages over fluores-
cence [14]. First, Raman spectroscopy needs no external la-
beling as the contrast is based on endogeneous optical
properties of the biological tissue. The contrast is generated
in the cross section for Raman scattering due to induced
polarizability generated in the tissue upon irradiation. Ra-
man scattering is inelastic scattering, and measuring the
difference between the energy of the incident photons and
scattered photons one can obtain the information about vi-
brations. Therefore, biochemical signatures of the mole-
cules obtained from the Raman spectroscopy are richer
than those from the fluorescence spectroscopy. For ex-
ample–nucleic acids, lipids, biological chromophores and
proteins are characterized by narrow vibrational peaks in
different spectral regions, in contrast to broad, largely un-
specific emission profiles obtained in the fluorescence
method. Second, Raman imaging (RI) has now reached a
level of sophistication that makes it competitive with more
conventional methods of confocal fluorescence microscopy
in terms of sensitivity, specificity, and spatial resolution.
Optical Raman imaging has emerged as a new modality
which enables real time, non-invasive, high resolution im-
aging of epithelial tissue, with a particular focus in this paper
on breast cancer diagnosis [15-34]. The method has a poten-
tial to replace the conventional biopsy and histopathological
analysis by an optical Raman biopsy [35-39]. Due to confocal
microendoscopy advancements, optically fiber coupled spec-
trometers and semiconductor technology it becomes pos-
sible to perform the in vivo mode of operation in real time.
Raman scattering efficiency can be enhanced by fac-
tors >108 when a substance is adsorbed on or near rough
metal surfaces. The Raman scattering amplification associ-
ated with this phenomenon is known as surface-enhanced
Raman scattering (SERS) spectroscopy [40]. These huge
increases in Raman scattering are primarily caused by the
increased intensity of the electromagnetic fields present at
the surface of these metals. SERS preserves the essentialfeatures of Raman scattering, yet the surface enhancement
provided by the metal nanoparticle allows unique spectra
to be acquired from a variety of adsorbed species.
The enhancement can further increase even up to 11 or-
ders and reach a limit of detection of 10-16 M in surface-
enhanced resonance Raman spectroscopy (SERRS) [41,42],
13 orders in surface-enhanced Raman scattering–scanning
near-field optical microscopy (SERS–SNOM) [31] or even
14–15 orders of magnitude and detection down to
10-10–10-14 M in non-linear optical microscopy (e.g. coher-
ent anti-Stokes Raman scattering (CARS)) [43-46].
Therefore, with further advancements of SERS com-
bined with highly sensitive SERS active probes, Raman
techniques may open up a new direction in nanomedicine,
and bioimaging for high-sensitive high-throughput signal
detection, even down to the single-molecule level [44-46].
There is increasing evidence that Raman imaging can be
utilized to understand molecular mechanisms of breast
cancer [21,47,48]. It also has potential to be employed in
clinical applications for early diagnosis, recurrence predic-
tion and response to treatment measurement. Properly
chosen optically active contrast agents and targeted bio-
markers that monitor functional features of cancer can
greatly contribute to the development of nucleic acid and
protein-based diagnostic tests by Raman methods. The de-
sign of proper SERS–based biotags requires a complex
interplay of biological interactions for increasing the num-
ber of fluorescent proteins or nanoparticles, which is cur-
rently at early stages of research and development [48,49].
This paper will focus on new developments in breast
cancer biochemical imaging, as well as exploring the po-
tential of clinical applications. The aim of the present
study is to demonstrate that the label-free Raman imaging
has the ability to accurately characterize breast cancer tis-
sue and distinguish between noncancerous and cancerous
types. We will demonstrate how this knowledge contrib-
utes to new branches of diagnostic developments for
breast cancer diseases. The results presented in this paper
demonstrate that Raman imaging has significant potential
for probing human breast tissue to provide complemen-
tary data in the early diagnosis of breast cancer.
Results
In this section we present the results of the Raman and IR
studies on the noncancerous and cancerous human breast
tissues. Having reached this point when we have established
the proper protocol of tissue preparation to obtain reliable
results from IR and Raman measurements, we will explore
vibrational spectroscopy and imaging for a variety of bio-
medical applications, particularly molecular diagnostics
of breast cancer. Details of the protocol are provided in
Additional file 1, available at [URL].
Figure 1(A,B,C) shows the microscope image, a typical
Raman image, and Raman spectra of the noncancerous
Figure 1 (See legend on next page.)
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Figure 1 Raman image and spectra of the noncancerous and cancerous breast tissue of the patient P81. Noncancerous breast tissue: (A)
Microscope image, (B) Raman image (400x400 μm) from the region marked in (A), (C) Raman spectra (integration time: 0.05 s). Cancerous breast
tissue: (D) Microscope image, (E) Raman image (300x300 μm) from the region marked in (D), (F) Raman spectra (integration time: 0.036 s). The
colors of the spectra correspond to the colors in the image. Mixed areas are displayed as mixed colors.
Figure 2 Raman spectra of the noncancerous tissue of the
patient P81. Raman spectra were obtained from various points in
the sample from the regions marked with crosses. The colors of the
spectra correspond to the colors of the crosses.
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safety margin for one of the patients. The total number of
patients used in Raman measurements is 200 [15-21]. One
can see that the Raman images reveal distinct structures
corresponding to inhomogeneous distribution of different
compounds in the monitored area. At the first glance, the
Raman image (Figure 1(B)) spectacularly resembles a
microscope image (Figure 1(A)). The advantage of the ‘Ra-
man biopsy’ is that it provides direct biochemical informa-
tion (vibrational fingerprint) in real time and is not prone
to subjective interpretations. Moreover, it monitors the
biological tissue structures without any external agents, in
contrast to histological assessment [18-21].
In order to identify human breast structures and the
corresponding biochemical constituents that produce the
Raman vibrational pattern of behavior, we have recorded
the Raman image for the cancerous breast tissue of the
same patient P81. Figure 1(D,E,F) shows the typical micro-
scope image, a Raman image and Raman spectra of the
breast cancerous tissue (infiltrating ductal carcinoma) (of
the same patient as in Figure 1(A,B,C). These Raman
spectra have been used as the references basis spectra (see
Additional file 1 [URL]) to produce the Raman images.
The first observation that one makes when confronting
the results obtained are noticeable differences between the
Raman spectra and Raman images of the noncancerous
breast tissue surrounding tumor from the safety margin
(Figure 1(B,C)) and the cancerous breast tissue from the
tumor mass (Figure 1(E,F)). The yellow areas in Figure 1
(B) represent adipose tissue with red areas corresponding
to the membranes of the adipose cells filling spaces
around the lobules and the ducts. In contrast, the blue
and green colors represent strongly autofluorescent struc-
tures. The pink and red areas shown in Figure 1(E) repre-
sent proteins in the cancerous breast tissue, which are not
visible in the normal tissue in Figure 1(B). This finding
corresponds to the fact that in contrast to normal cells,
the abnormal cells divide in uncontrolled process of cell
growth that synthesizes large amounts of proteins.
Significant differences observed in Raman spectra indi-
cate marked distinctions in biochemical composition and
distribution of biochemical components. In the next sec-
tion we will demonstrate that the contrast in Raman im-
ages is dominated by carotenoids, fatty acids, proteins and
water. We will show that the normal breast tissue sur-
rounding the tumor contains a markedly higher concentra-
tion of fatty acids and carotenoids as compared to that of
the cancerous tissue. The higher β-carotene content innormal breast tissue was also found by diffuse reflectance
spectroscopy [50]. The cancerous breast tissue has a differ-
ent profile of vibrational features indicating distinct lipids
composition and a much higher contribution from
proteins.
Discussion
In the view of the results presented in the previous sec-
tion we first need to identify the main biochemical con-
stituents of human breast tissue that contribute to the
Raman vibrational pattern of behaviour. Figure 2 shows
the typical Raman spectra of the noncancerous tissue,
which were obtained from various points of the sample.
The Raman spectra of the noncancerous tissue shows
peaks at 877, 1004, 1158, 1304, 1444, 1518, 1660, 1750,
2854, 2888, 2926, and 3009 cm-1. The Raman spectra at
1158 and 1518 cm-1 have been assigned to carotenoids.
The bands at 1158 and 1518 cm-1 represent the
stretching mode of C-C and C=C bond of the polyene
Figure 3 Raman and IR spectra for the noncancerous and
cancerous breast tissues (infiltrating ductal carcinoma). (A)
Raman spectra of the patient P81; (B) IR spectra of the patient P83;
(C) Raman spectrum for the noncancerous normal breast tissues of
the patient P81 and IR spectrum for the noncancerous normal
breast tissues of the patient P83; (D) Raman spectrum for the
cancerous breast tissues of the patient P81 and IR spectrum for the
cancerous breast tissues of the patient P83.
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1660, 1750, 2854, 2888, 2926 and 3009 cm-1 have been
assigned to fatty acids of the adipose tissue contained in
the normal breast structure. The comparison with the
Raman spectra of the essential fatty acids ω-3 and ω-6
shows that the normal tissue is dominated primarily by
oleic acid derivatives [19,21]. The assignment of the Ra-
man peaks observed in the noncancerous breast tissue is
presented in Additional file 1: Table S1 [URL].
Figure 3(A) compares the Raman spectra for the
noncancerous and cancerous breast tissues of the patient
P81 (infiltrating ductal carcinoma). The cancerous tissue
displays only a limited number of Raman peaks at 558,
1098, 1269, 1444, 1660, 2888, 2926, 2940 and 3311cm-1.
The assignment of the Raman peaks observed in the
cancerous breast tissue is presented in Additional file 1:
Table S2 [URL].
One of the most remarkable aspects of the comparison
are marked differences between the Raman spectra of
the noncancerous and cancerous tissues. The most pro-
nounced differences can be seen in the biochemical
composition and distribution of carotenoids (1158 and
1518 cm-1), lipids (2800–3000 cm-1) and water repre-
sented by the OH stretching band at 3311 cm-1.
To obtain complementary information on vibrational
features of the normal and cancerous tissues, it would
be very interesting to compare the Raman spectra with
IR spectra. Figure 3(B) shows the comparison between
the IR spectra of the noncancerous tissue and cancerous
breast tissue.
The comparison between the IR results of the patient
P83 (infiltrating ductal carcinoma) presented in Figure 3
(B) demonstrates that the vibrational peaks for the
noncancerous and cancerous breast tissues are very
similar. The differences in Figure 3(B) are related to the
magnitudes of absorbance in the region of 2800–3500
cm-1, 1740 cm-1, 1444 cm-1, 972 cm-1.
In the view of the results presented in Figure 3(A) and
(B) it is clearly visible that the Raman method demon-
strates a markedly higher specificity allowing to distingui-
shing between the normal and cancerous breast tissues,
thus having the potential to be a better diagnostic tool in
breast cancer pathology.
In order to rationalize the vibrational features of the can-
cer pathology monitored by IR and Raman spectroscopy
Figure 4 H-bond interactions of interfacial water at biological
interfaces. (A) dry sample, (B) wet sample; the blue line through
the cartoon represents the tissue/water interfaces. The orange and
green sites represent the hydrophilic moieties on the surface of the
tissue. The red and white circles represent the oxygen and hydrogen
atoms in water molecules, respectively.
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cancerous breast tissues. Figure 3(C) compares Raman and
IR spectra for the noncancerous breast tissues.
A detailed inspection into Figure 3(C) demonstrates
that the vibrations originating from carotenoids at 1158
cm-1 and 1518 cm-1, which are the strongest signals in
the Raman spectrum, are not visible in the IR spectrum.
The reason is quite obvious, and that is because the ex-
citation with 514 nm leads to the resonance Raman en-
hancement of carotenoids, which is not present in IR
measurements. The IR spectra of the noncancerous tis-
sue shows peaks at 1444, 1660, 2854, 2888, 2926 cm-1
just like Raman spectra. Additional peaks at 842, 972,
1116, 1240, 1560, 1740 cm-1 are clearly visible in the IR
spectrum. The marked distinctions can be observed in the
lipid-protein profiles in the region of 2800–3000 cm-1,
where the contribution from the monounsaturated fatty
acids that are common constituents of triglycerides of the
adipose tissue dominates the Raman spectrum [19] in con-
trast to the IR spectra that demonstrate a more protein
like profile. These differences originate from different
selection rules for the Raman spectroscopy and IR spect-
roscopy. Namely, a change of molecular polarization cor-
responding to deformation of the electronic cloud around
the chemical bound with respect to the vibrational coord-
inate is required for a molecule to exhibit a Raman signal.
In contrast, a change of molecular dipole with respect to
the vibrational coordinate is required for a molecule to
exhibit an IR signal.
The most pronounced differences can be seen in the re-
gion of water represented by the OH stretching vibrations,
a strong IR band at 3348 cm-1 is observed as opposed to
the Raman spectrum, where no water signal is present.
Figure 3(D) compares Raman and IR spectra for the
cancerous breast tissues. In contrast to the noncancerous
tissue the differences are less spectacular. First, the Raman
spectra of the cancerous tissue show no signals from ca-
rotenoids like IR spectra. Second, the lipid-protein profiles
of IR and Raman spectra in the region 2800–3000 cm-1
are similar, unlike in the case of the normal tissue. Third,
both Raman and IR spectra demonstrate contribution
from water. The apparently single bands are observed at
3348 cm-1 for IR and 3311 cm-1 for Raman, which we have
assigned to the OH stretching mode of water. The main
difficulty in interpretation of the Raman (and IR bands) in
the region of 3000–3600 cm-1 comes from the fact that lo-
cation of bands of water may overlap with the N-H
stretching bands of proteins (amide A at 3365 cm-1) and
N-H stretching vibrations of DNA. The detailed discus-
sion of this assignment has been presented in reference
[24]. It is worth emphasizing that the OH stretching re-
gion of water in the breast tissue with the single band dif-
fers markedly from that of the bulk water represented by a
double structure with the maximum band positions at3258 cm-1 and 3410 cm-1 [18]. It indicates that the charac-
teristic vibrational features of water molecules near a bio-
logical interface, where the H-bond network gets locally
disrupted, differ significantly from those of bulk water due
to interactions with the hydrophilic sites of the tissue.
Water in the breast tissue is very likely present as inter-
facial molecules, with one bond hydrogen bonded to some
hydrophilic moieties in the tissue (e.g. proteins or lipid
head), and the second bond being free (Figure 4(A)) or in-
volved in H-bond interactions with another water mole-
cules (Figure 4(B)) [18]. The single Raman peak at 3311
cm-1 in Figure 3(A) (3348 cm-1 in IR, Figure 3(B)) has
been assigned to the stretching vibration of the OH bond,
which is decoupled from the other OH bond of a water
molecule. The mechanism of decoupling is related to
breaking of the C2ν symmetry similar to that observed in
water diluted in deuterated water, where the HDO species
are generated as a result of isotopic exchange. Breaking of
the C2v symmetry comes from nonequivalent interactions
of the O-H bonds of the water molecules in the biological
tissue - one of the OH bonds interacts with the hydro-
philic sites of the tissue (blue OH bond in Figure 4), the
other OH is almost quasi free and not involved in any H-
bond interactions (dry sample in Figure 4(A)–when there
is a limited number of water molecules at the interface) or
interacts with other water molecules of the H-bond net-
work (wet sample in Figure 4(B))–when there is a suffi-
cient number of water molecules at the interface). This
mechanism illustrated in Figure 4 seems to occur for the
surface water at biological interfaces.
The important question arises why IR spectroscopy
identifies interfacial water in the spectral region of
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cancerous tissues (see Figure 3(B) and Additional file 1:
Figure S3, [URL]) in contrast to Raman spectroscopy, where
only cancerous tissue exhibits vibrational features of water
(see Figure 3(A)). It can be explained by the different config-
urations of the optical paths in Raman and IR techniques
(Additional file 1: Figure S1, [URL]). The Raman spectros-
copy measures the Raman signal scattered back from the tis-
sue. The IR methods measures the signal transmitted
through the tissue thin section attached to the window
(BaF2). Therefore, the layer of external, ambient water is
confined between the tissue section and the surface of the
window, giving the contribution to the IR spectrum both in
the noncancerous and the cancerous tissues. The ambient
water cannot be removed by the reference beam, because
the amount of water attached to the empty window differs
from that confined under the tissue slice. In the Raman
measurements the laser penetration depth is around 30 μm
at 514 nm and allows to reaching the layer of water between
the microscope glass and the tissue slice of 2 μm. However,
in the confocal Raman microscopy the laser beam is focused
exactly on the tissue and the back scattered Raman signal
originates only from the tissue. As a result, the Raman signal
is dominated by the water molecules confined within the tis-
sue in contrast to the IR signal originating largely from the
absorption of water from the space between the tissue and
the window (Additional file 1: Figure S1, [URL]).
The detailed inspection into Figure 3(A) shows the
spectacular differences in the Raman spectra of the OH
band of water in the noncancerous and cancerous breast
tissues. The noncancerous tissue shows a negligible sig-
nal of water when compared to the cancerous tissue
where the signal peak at 3311 cm-1 is observed. The lack
of water is likely due to higher content of hydrophobicFigure 5 Raman images. (A) noncancerous and (B) cancerous breast tissu
cm-1), proteins (2930 cm-1) and autofluorescence (1800 cm-1).adipose tissue in the noncancerous tissue. Indeed, the
Raman images presented in this paper show evidently
that the breast structure of the noncancerous tissue con-
tains a significantly higher content of the adipose cells
(demonstrated in the Raman imaging by the yellow color
in Figure 1(B) than the cancerous tissue (Figure 1(E))
that shows negligible amount of the adipose tissue.
In the view of the results presented so far one can
state that there are four important Raman markers of
breast tissue - carotenoids, fatty acids, proteins and
water. Our results demonstrate that there is an intri-
guing correlation between the amount of monounsatu-
rated fatty acids, carotenoids and water in the breast
tissue. First, we will concentrate on the link between ca-
rotenoids and monounsaturated fatty acids. Recently, we
have shown that oleic acid exists as a separate phase
within the noncancerous human breast tissue [19]. The
question arises whether we are capable of learning from
Raman imaging about areas of the breast tissue structure
in which carotenoids and monounsaturated fatty acids
are accumulated. Answering this question may be re-
lated to the primary mechanisms of carcinogenesis. Sev-
eral physiological functions have been attributed to
carotenoids, particularly an upregulation of gap junc-
tional communication (GJC) in connexins [51,52]. There
is growing evidence that the GJC plays an important role
in the regulation of morphogenesis, cell differentiation,
secretion of hormones, and growth as well as in human
diseases including human breast cancer [53].
In order to monitor accumulation of carotenoids and
fatty acids in localized regions of the tissue presented in
Figures 1(B) and (E) we have employed various spectral
filters in the Raman images to analyze different areas of
the noncancerous and cancerous breast tissues. Figure 5e, Filters: carotenoids (1518 cm-1), monounsaturated fatty acids (2854
Figure 6 (See legend on next page.)
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Figure 6 Raman spectra of fatty acids compared with the Raman spectra of cancerous and noncancerous breast tissues. (A) 1A - oleic
acid (OA), 2A - linoleic acid (LA), 3A - α-linolenic acid (ALA), 4A - eicosapentaenoic acid (EPA), 5A - docosahexaenoic acid (DHA), (B) 1B - oleic acid
(OA), 2B - linoleic acid (LA), 3B - γ-linolenic acid (GLA), 4B - arachidonic acid (AA). (C) Comparison between the Raman spectrum of the cancerous
tissue (patient P81) and the spectrum of a muscle tissue from pork meat (Pr 24).
Surmacki et al. Molecular Cancer 2013, 12:48 Page 10 of 12
http://www.molecular-cancer.com/content/12/1/48shows the Raman images for the noncancerous (Figure 5
(A)) and cancerous (Figure 5(B)) breast tissue for the fil-
ters at 1518 cm-1, 2854 cm-1, 2930 cm-1 and 1800 cm-1
corresponding to the vibrational frequency of caroten-
oids, oleic acid, proteins and autofluorescence, respect-
ively. One can see that for the noncancerous tissue the
Raman image at the filter 1518 cm-1 (Figure 5(A)) illus-
trating the distributions of carotenoids is almost identi-
cal as that for the filter 2854 cm-1 for unsaturated fatty
acids and triglycerides. It clearly indicates that the unsat-
urated fatty acids and triglycerides of the adipose tissue
act as a dynamic reservoir that supplies carotenoids to
the human organs. In contrast, the cancerous breast tis-
sue does not contain any carotenoids as demonstrated
by Figure 5(B) at the filter 1518 cm-1. The pink areas in
Figure 5(B) at the filter 2930 cm-1 illustrate the distribu-
tion of proteins in the cancerous breast tissue. The com-
parison of the images of fluorophores in the tissues (at
the filter 1800 cm-1) in Figure 5(A) and (B) demonstrates
that the fluorescent species (blue areas) in the cancerous
tissue are accumulated in similar regions as the proteins
(pink areas) in contrast to the noncancerous tissue,
where the fluorophores are accumulated in the regions
complementary to those of the monounsaturated fatty
acids and carotenoids (yellow and red areas).
The main difficulty in interpretation of the Raman and
IR bands in the region of 2800–3000 cm-1 comes from
the fact that the spectral region of the bands of fatty
acids and lipids overlap with the bands of proteins. The
main protein band near 2940 cm-1 attributed to aromatic
and aliphatic amino acids and many other amino acids
overlaps with the characteristic C-H bands of fatty acids
[24] attributed to a variety of CH, CH2, and CH3 groups
in the side chains. Fortunately, a band at 3009 cm-1, cor-
responding to H-C=C vibrations, which is clearly visible
in fatty acids (Figure 6(A,B)), is relatively weak in most
proteins and may help to identify dominating compo-
nents of the tissue in this spectral region.
Figure 6(A,B) compares Raman spectra of selected
fatty acids with the Raman spectra of the noncancerous
and cancerous breast tissue. Detailed inspection into
Figure 6 (A) and (B) shows that the noncancerous tissue
contains the 3009 cm-1 vibration typical for fatty acids in
contrast to the cancerous tissue that reveals no contri-
bution from 3009 cm-1 component. To check the contri-
bution from proteins we have compared the Raman
spectrum of the cancerous tissue with the spectrum of a
muscle tissue taken from pork meat, which is dominatedby a protein component. Figure 6(C) shows the compari-
son of the Raman spectrum of the cancerous breast tis-
sue of the same patient as in the previous figures with
the spectrum of a muscle tissue from pork meat. One
can see from Figure 6(B) that the profile of the cancer-
ous tissue is very similar to the protein component with
significant contribution of the bands at 2930–2940 cm-1
from proteins and no sign of contribution of the band at
3009 cm-1 from fatty acids. The main band of proteins
typically at 2939–2944 cm-1 is due to the aromatic and
aliphatic amino acids, the charged amino acids and pro-
line, threonine, and histidine. In contrast to the bands
near 2930–2940 cm-1, the bands near 2880 and 3056
cm-1 may reflect predominantly aliphatic and aromatic
groups, respectively [54]. The growing contribution from
the protein components is a well known indicator of car-
cinogenesis [55]. Approximately 30% of breast cancers
have an amplification of the HER2/neu gene or
overexpression of its protein HER2 product.
Conclusions
This study has illustrated important aspects of Raman
reporters that may be used to characterize human breast
tissue at a biochemical molecular level. A number of vi-
brational features in the C-H stretch region change dur-
ing the process of transformation of the normal breast
tissue into the cancerous tissue. These changes may be
used to monitor conformational changes of fatty acids,
hydrophobic interactions, denaturation, as well as con-
formational changes of proteins. The biochemical infor-
mation obtained from the Raman imaging will be
particularly useful in monitoring how breast epithelial
cells respond to signals from the extracellular matrix
(ECM) and how cells lose their normal interactions with
the ECM during cancer progression. Raman imaging will
help to monitor an increased deposition of ECM pro-
teins and fibroblasts in the stroma surrounding the epi-
thelial cells which is a leading risk factor for breast
carcinoma. As a result Raman imaging may help to
understand the mechanisms by which stromal density
could promote breast carcinoma.
We have found that Raman spectra and Raman images
are sensitive indicators of the distribution of main con-
stituents of breast tissue structure such as lipids, pro-
teins, fatty acids, carotenoids and water. The Raman
images show evidently that the noncancerous breast tis-
sue contains a significant contribution from triglycerides
originating from the adipose tissue filling the spaces
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up the cell membrane and nuclear membrane. The can-
cerous tissue is dominated by the protein component.
We have found that the water amount confined in the
cancerous tissue is markedly higher than in the
noncancerous tissue. The OH stretching vibrations of
water, C-C,C=C stretching vibrations of carotenoids,
2930–2940 cm-1 vibrations of proteins, and 2800–3009
cm-1 vibrations of fatty acids can be useful as potential
Raman biomarkers to distinguish between the cancerous
and the noncancerous human breast tissues. Our results
provide experimental evidence for the role played by the
lipid-protein-carotenoid profile and cell hydration as fac-
tors of particular significance in differentiation of the
non-cancerous and cancerous breast tissues.
Our further studies will concentrate on a detailed un-
derstanding of interfacial water at the biological surfaces
of the cancerous human tissue, where the crowded en-
vironment of many biomolecules introduces its own “hy-
dration fingerprint”. It is one of the most important
topics in molecular biology because it will not only im-
prove our current knowledge about water itself but also
lead to significant advances in our understanding of the
structure and process with which confined water is asso-
ciated (protein folding, hydrophobic assemblies, bio-
logical membranes).
Methods
All procedures were conducted under a protocol ap-
proved by the institutional Bioethical Committee at the
Medical University of Lodz, Poland (RNN/29/11/KE,
RNN/30/11/KE, RNN/31/11/KE).
Detailed methodology is available in Additional file 1,
available at [URL].
Additional file
Additional file 1: Figure S1. Illustration of measurement techniques:
transmission IR spectroscopy and confocal Raman scattering microscopy.
Figure S2. IR spectra of the noncancerous and cancerous (infiltrating ductal
carcinoma) human breast tissue slices (patient P81) (a) on the microscope
glass of paraffin-embeddeded, nonstained tissue ; (b) the histological samples
after deparaffinization, staining and coating with a standard adhesive
(Histokitt, Glaswarenfabrik Karl Hecht GmbH & Co KG); (c) IR spectrum of the
adhesive (Histokitt) and paraffin. Figure S3. IR spectra of the noncancerous
and cancerous (infiltrating ductal carcinoma) human breast tissue. Slices
obtained from cryosectioning on the glass window, patient P81. Table S1.
Assignments of the major bands for Raman and IR spectra of the
noncancerous human breast tissue. Table S2. Assignments of the major
bands for Raman and IR spectra of the cancerous human breast tissue.
Abbreviations
IR: infrared; MRI: magnetic resonance imaging; PET: positron emission
tomography; PEM: positron emission mammography; RI: Raman imaging;
SERS: surface-enhanced Raman scattering; Microscopy (SERS–SNOM): surface-
enhanced Raman scattering–scanning near-field optical; CARS: coherent anti-
Stokes Raman scattering; DNA: deoxyribonucleic acid; GJC: gap junctional
communication; HER2/neu: human epidermal growth factor receptor 2;OA: Oleic acid; LA: Linoleic acid; ALA: α-linolenic acid; EPA: Eicosapentaenoic
acid; DHA: Docosahexaenoic acid; OA: Oleic acid; LA: Linoleic acid; GLA: γ-
linolenic acid; AA: Arachidonic acid.
Competing interests
All authors declare that they do not have any competing interests.
Authors’ contributions
JS performed most of the experiments, analyzed the data, preparing the
figures and tables, JM prepared histological samples, examined histological
specimens, RK participated in designed carcinogenesis study, HA participated
in designed carcinogenesis study, analyzed the data and interpretation of
the results. All authors read and approved the final manuscript.
Acknowledgement
The research work has been financed through the Dz. St. 2013.
The authors thank the entire surgical and pathology staff at the Medical
University of Lodz and Synevo for their assistance in the research. The
authors acknowledge also Dr. Elena Bailo and Dr. Thomas Dieing from WITec
(Ulm, Germany) for their technical support and for valuable insights.
Author details
1Laboratory of Laser Molecular Spectroscopy, Institute of Applied Radiation
Chemistry, Lodz University of Technology, Wroblewskiego 15, Lodz 93-590,
Poland. 2Department of Pathology, Chair of Oncology, Medical University of
Lodz, Paderewskiego 4, Lodz 93-509, Poland.
Received: 19 December 2012 Accepted: 22 May 2013
Published: 24 May 2013
References
1. Obi N, Waldmann A, Schäfer F, Schreer I, Katalinic A: Impact of the quality
assured mammadiagnostic (QuaMaDi) programme on survival of breast
cancer patients. Cancer Epidemiol 2011, 35:286–292.
2. Bird RE, Wallace TW, Yankaskas BC: Analysis of Cancers Missed at
Screening Mammography. Radiology 1992, 184:613–617.
3. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW: Ten-Year
Risk of False Positive Screening Mammograms and Clinical Breast
Examinations. N Engl J Med 1998, 338:1089–1096.
4. Takei J, Tsunoda-Shimizu H, Kikuchi M, Kawasaki T, Yagata H, Tsugawa K,
Suzuki K, Nakamura S, Saida Y: Clinical implications of architectural
distortion visualized by breast ultrasonography. Breast Cancer 2009,
16:132–135.
5. Le-Petross HT, Shetty MK: Magnetic resonance imaging and breast
ultrasonography as an adjunct to mammographic screening in high-risk
patients. Semin Ultrasound CT MR 2011, 32:266–272.
6. Avril N, Adler LP: F-18 fluorodeoxyglucose-positron emission tomography
imaging for primary breast cancer and loco-regional staging. Radiol Clin
North Am 2007, 45:645–657.
7. Nass SJ, Henderson IC, Lashof JC: Mammography and Beyond: Developing
Technologies for the Early Detection of Breast Cancer. Washington, DC:
National Academy Press; 2001.
8. Abreu MC, Almeida P, Balau F, Ferreira NC, Fetal S, Fraga F, Martins M,
Matela N, Moura R, Ortgao C, Peralta L, Rato P, Ribeiro R, Rodriques P,
Santos AI, Trindade A, Varela J: Clear-PEM: A dedicated PET camera for
improved breast cancer detection. Radiat Prot Dosim 2005, 116:208–210.
9. Tromberg BJ, Pogue BW, Paulsen KD, Yodh AG, Boas DA, Cerussi AE:
Assessing the future of diffuse optical imaging technologies for breast
cancer management. Med Phys 2008, 35:2443–2451.
10. Schulz RB, Peter J, Semmler W, D’Andrea C, Valentini G, Cubeddu R:
Comparison of noncontact and fiber-based fluorescence-mediated
tomography. Opt Lett 2006, 31:769–771.
11. Mienkina MP, Friedrich CS, Gerhardt NC, Beckmann MF, Schiffner MF, Hofmann
MR, Schmitz G: Multispectral photo-acoustic coded excitation imaging using
unipolar orthogonal Golay codes. Opt Ex. 2010, 18:9076–9087.
12. Ramaz F, Forget BC, Atlan M, Boccara AC, Gross M, Delaye P, Roosen G:
Photorefractive detection of tagged photons in ultrasound modulated
optical tomography of thick biological tissues. Opt Exp 2004, 12:5469–5474.
13. Denk W, Strickler JH, Webb WW: Two-photon laser scanning fluorescence
microscopy. Science 1990, 248:73–76.
Surmacki et al. Molecular Cancer 2013, 12:48 Page 12 of 12
http://www.molecular-cancer.com/content/12/1/4814. Dieing T, Hollricher O, Toporski J: Confocal Raman Microscopy. Dordrecht
London New York: Springer Heidelberg; 2011. ISBN ISBN: 978-3-642-12521-8.
15. Abramczyk H, Surmacki J, Brożek–Płuska B, Morawiec Z, Tazbir M: The hallmarks
of breast cancer by Raman spectroscopy. J Mol Struc 2009, 924–926:175–182.
16. Brożek–Płuska B, Placek I, Kurczewski K, Morawiec Z, Tazbir M, Abramczyk H: Breast
cancer diagnostics by Raman spectroscopy. J Mol Liquid 2008, 141:145–148.
17. Abramczyk H, Placek I, Brożek-Płuska B, Kurczewski K, Morawiec Z, Tazbir M:
Human breast tissue cancer diagnosis by Raman spectroscopy.
Spectroscopy 2008, 22:113–121.
18. Abramczyk H, Brozek-Pluska B, Surmacki J, Jablonska-Gajewicz J, Kordek R:
Hydrogen bonds of interfacial water in human breast cancer tissue
compared to lipid and DNA interfaces. JBPC 2011, 2:158–169.
19. Brozek-Pluska B, Jablonska-Gajewicz J, Kordek R, Abramczyk H: Phase
transitions in oleic acid and in human breast tissue as studied by Raman
spectroscopy and Raman imaging. J Med Chem 2011, 54:3386–3392.
20. Abramczyk H, Brozek-Pluska B, Surmacki J, Jablonska J, Kordek R: The label-free
Raman imaging of human breast cancer. J Mol Liq 2011, 164:123–131.
21. Abramczyk H, Brozek-Pluska B, Surmacki J, Jablonska-Gajewicz J, Kordek R: Raman
‘optical biopsy’ of human breast cancer. Prog Biophys Mol Biol 2012, 108:74–81.
22. Santos L, Wolthuis R, Koljenovic S, Almeida RM, Puppels GJ: Fiber-optics
probes for in-vivo Raman spectroscopy in the high wavenumber region.
Anal Chem 2005, 77:6747–6752.
23. Alfano RR, Liu CH, Sha WL, Zhu HR, Akins DL, Cleary J, Prudente R, Cellmer
E: Human breast tissues studied by IR Fourier transform Raman
spectroscopy. Lasers Life Sci 1991, 4:23–28.
24. Frank CJ, Redd DCB, Gansler TS, McCreery RL: Characterization of human
breast biopsy specimens with near-IR Raman spectroscopy. Anal Chem
1994, 66:319–326.
25. Manoharan R, Shafer K, Perelman RT, Wu J, Chen K, Deinum G, Fitzmaurice
M, Myles J, Crowe J, Dasari RR, Feld MS: Raman spectroscopy and
fluorescence photon migration for breast cancer diagnosis and imaging.
Photochem Photobiol 1998, 67:15–22.
26. Motz JT, Gandhi SJ, Scepanovic OR, Haka AS, Kramer JR: Real-time Raman
system for in vivo disease diagnosis. J Biomed Opt 2005, 10:031113–031117.
27. Choo-Smith LP, Edwards HGM, Enditz HP, Kros JM, Heule F, Barr H, Robinson JS,
Bruining HA, Puppels GJ: Medical applications of Raman spectroscopy: From
proof of principle to clinical implementation. Biopolymers 2002, 67:1–9.
28. Shafer-Peltier KE, Haka AS, Fitzmaurice M, Crowe J, Myles J, Dasari RR, Feld
MS: Raman microspectroscopic model of human breast tissue:
implications for breast cancer diagnosis in vivo. J Raman Spectroscopy
2002, 33:552–563.
29. Baker R, Matousek P, Ronayne KL, Parker AW, Rogers K, Stone N: Depth
profiling of calcifications in breast tissue using picosecond Kerr gated
Raman spectroscopy. Analyst 2007, 132:48–53.
30. Owen C, Notingher I, Hill R, Stevens M, Hench L: Progress in Raman
spectroscopy in the fields of tissue engineering, diagnostics and
toxicological testing. Mater Med 2006, 17:1019–1023.
31. Short KW, Carpenter S, Freyer JP, Mourant JR: Raman spectroscopy detects
biochemical changes due to proliferation in mammalian cell cultures.
Biophys J 2005, 88:4274–4288.
32. Kneipp J, Tom BS, Kliffen M, Marian MP, Puppels G: Characterization of breast
duct epithelia: a Raman spectroscopic study. Vib Spectrosc 2003, 32:67–74.
33. Chowdary MVP, Kumar KK, Kurien J, Mathew S, Krishna CM: Discrimination
of normal, benign, and malignant breast tissues by Raman spectroscopy.
Biopolymers 2006, 83:556–569.
34. Chowdary PD, Jiang Z, Chaney EJ, Benalcazar WA, Marks DL, Gruebele M,
Boppart SA: Molecular histopathology by spectrally reconstructed nonlinear
interferometric vibrational imaging. Cancer Res 2010, 70:9562–9569.
35. Saha A, Barman I, Dingari NC, McGee S, Volynskaya Z, Galindo LH, Liu W,
Plecha D, Klein N, Dasari RR, Fitzmaurice M: Raman spectroscopy: a real-
time tool for identifying microcalcifications during stereotactic breast
core needle biopsies. Biomed Opt Exp 2011, 2:2792–2803.
36. Dingari NC, Barman I, Saha A, McGee S, Galindo LH, Liu W, Plecha D, Klein N,
Dasari RR, Fitzmaurice M: Development and comparative assessment of Raman
spectroscopic classification algorithms for lesion discrimination in stereotactic
breast biopsies with microcalcifications. J Biophotonics 2012, 6:371–381.
37. Stone N, Baker R, Rogers K, Parker AW, Matousek P: Subsurface probing of
calcifications with spatially offset Raman spectroscopy (SORS): future
possibilities for the diagnosis of breast cancer. Analyst 2007, 132:899–905.
38. Stone N, Matousek P: Advanced transmission Raman spectroscopy: a
promising tool for breast disease diagnosis. Cancer Res 2008, 68:4424–4430.39. Saha A, Barman I, Dingari NC, Galindo LH, Sattar A, Liu W, Plecha D, Klein N,
Dasari RR, Fitzmaurice M: Precision of Raman spectroscopy measurements
in detection of microcalcifications in breast needle biopsies. Anal Chem
2012, 84:6715–6722.
40. Graham D, Faulds K: Quantitative SERRS for DNA sequence analysis. Chem
Soc Rev 2008, 37:1042–1051.
41. Zeisel D, Deckert V, Zenobi R, Vo-Dinh T: Near-field surface-enhanced
Raman spectroscopy of dye molecules adsorbed on silver island films.
Chem Phys Lett 1998, 283:381–385.
42. Chowdary J, Sarkar J, Tanaka T, Talapatra GB: Concentration dependent
orientational changes of 2-amino-2-thiazoline molecule adsorbed on
silver nanocolloidal surface investigated by SERS and DFT. J Phys Chem
2008, 112:227–239.
43. Jarvis RM, Goodacre R: Characterization and identification of bacteria
using SERS. Chem Soc Rev 2008, 37:931–936.
44. Isola NR, Stokes DL, Vo-Dinh T: Surface enhanced Raman gene probe for
HIV detection. Anal Chem 1998, 70:1352–1356.
45. Haynes CL, Van Duyne RP: Plasmon-sampled surface-enhanced Raman
excitation spectroscopy. J Phys Chem B 2003, 107:7426–7433.
46. Kneipp K, Wang Y, Kneipp H, Perelman LT, Itzkan I, Dasari R, Feld MS: Single
molecule detection using surface-enhanced Raman scattering (SERS).
Phys Rev Lett 1997, 78:1667–1670.
47. Bailo E, Deckert V: Tip-enhanced Raman spectroscopy of single RNA
strands: Towards a novel direct-sequencing method. Angew Chem Int Ed
2008, 47:1658–1661.
48. Wang H, Vo-Dinh T: Multiplex detection of breast cancer biomarkers
using plasmonic molecular sentinel nanoprobes. Nanotechnology 2009,
20:065101-1–065101-6.
49. Cao YC, Jin R, Mirkin CA: Nanoparticles with Raman spectroscopic
fingerprints for DNA and RNA detection. Science 2002, 297:1536–1540.
50. Soares JS, Barman I, Dingari NC, Volynskaya Z, Liu W, Klein N, Plecha D,
Dasari RR: Diagnostic power of diffuse reflectance spectroscopy for
targeted detection of breast lesions with microcalcifications. Proc Natl
Acad Sci USA 2013, 110:471–476.
51. Lee SW, Tomasetto C, Paul D, Keyomarsi K, Sager RJ: Transcriptional
downregulation of gap-junction proteins blocks junctional
communication in human mammary tumor cell lines. Cell Biol 1992,
188:1213–1221.
52. Bertram JS: Induction of connexin 43 by carotenoids: functional
consequences. Arch Biochem Biophys 2004, 430:120–126.
53. Kumar NM, Gilula NB: The gap junction communication channel. Cell 1996,
84:381–388.
54. El-Bahy GMS: FTIR and Raman spectroscopy study of fenugreek
(Trigonella foenum graecum L.) seeds. J Appl Spectrosc 2005, 72:111–116.
55. Olayioye MA: Update on HER-2 as a target for cancer therapy:
Intracellular signaling pathways of ErbB2/HER-2 and family members.
Breast Cancer Res 2001, 3:385–389.
doi:10.1186/1476-4598-12-48
Cite this article as: Surmacki et al.: Raman imaging at biological interfaces:
applications in breast cancer diagnosis. Molecular Cancer 2013 12:48.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
